Medifoxamine is an atypical antidepressant drug that has been withdrawn from the market on account of its negative effects on the liver. It is different from the traditional and older drugs that are used to treat depression. It also has anti-anxiety effects and acts through dopamine and serotonin receptors in the brain. It is also known as an aromatic ether chemically.
It is different from tricyclic antidepressants as it does not have alpha blocking and anticholinergic effects. It has a low attraction to muscarinic acetylcholine receptors. Animal studies have shown that this drug does not have any sedative or stimulant effects. It is well-tolerated at doses of 100 to 300 milligrams per day as shown in some clinical trials. It is similar in efficacy to imipramine, clomipramine, and maprotiline in treating depression.
This drug was marketed in France, Spain, and Morrocco in the 1990s but was banned in the market because of hepatotoxicity. This drug is used to treat anxiety.
